Practical Management of Patients with Atopic Dermatitis on Dupilumab

Johnson FA(2017)Expert elicitation, uncertainty, and the value of information in controlling invasive species Ecol Econ 137 83-90

Smith BJ(2015)Systematic review of expert elicitation methods as a tool for source attribution of enteric illness Foodborne Pathog Dis 12 367-382

Bonneau M(2016)Two phase 3 trials of dupilumab versus placebo in atopic dermatitis N Engl J Med 375 2335-2348

Martin J(2017)Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial The Lancet 389 2287-2303

Romagosa C(2020)Dupilumab provides favorable safety and sustained efficacy for up to 3 years in an open-label study of adults with moderate-to-severe atopic dermatitis Am J Clin Dermatol 21 567-577

Mazzotti F(2020)Transitioning from immunosuppressants to dupilumab in pediatric atopic dermatitis Dermatitis 156 44-1293

Butler AJ(2020)An approach for the transition from systemic immunosuppressants to dupilumab J Eur Acad Dermatol Venereol 83 1282-87

Thomas MK(2020)Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial JAMA Dermatol 181 80-545

Pintar KDM(2020)Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial J Am Acad Dermatol 101 adv00402-149

Simpson EL(2019)Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator’s Global Assessment: a pooled analysis of data from two phase Br J Dermatol 156 131-404

Johnson FA(2017)Expert elicitation, uncertainty, and the value of information in controlling invasive species Ecol Econ 137 83-90

Smith BJ(2015)Systematic review of expert elicitation methods as a tool for source attribution of enteric illness Foodborne Pathog Dis 12 367-382

Bonneau M(2016)Two phase 3 trials of dupilumab versus placebo in atopic dermatitis N Engl J Med 375 2335-2348

Martin J(2017)Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial The Lancet 389 2287-2303

Romagosa C(2020)Dupilumab provides favorable safety and sustained efficacy for up to 3 years in an open-label study of adults with moderate-to-severe atopic dermatitis Am J Clin Dermatol 21 567-577

Mazzotti F(2020)Transitioning from immunosuppressants to dupilumab in pediatric atopic dermatitis Dermatitis 156 44-1293

Butler AJ(2020)An approach for the transition from systemic immunosuppressants to dupilumab J Eur Acad Dermatol Venereol 83 1282-87

Thomas MK(2020)Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial JAMA Dermatol 181 80-545

Pintar KDM(2020)Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial J Am Acad Dermatol 101 adv00402-149

Simpson EL(2019)Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator’s Global Assessment: a pooled analysis of data from two phase Br J Dermatol 156 131-404